Close Menu

More articles about Liquid Biopsy

The companies are developing a lung cancer liquid biopsy assay that will run on desktop sequencers, with plans to apply for regulatory clearance in China.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

ArcherDX said the firms aim to apply minimal residual disease monitoring in clinical-trial protocols and for future therapy optimization.

Lexent Bio's monitoring platform is in development and based on low-pass whole-genome sequencing and DNA methylation analysis.

The company is commercializing a genome-wide sequencing method called MRDetect, developed by researchers at the New York Genome Center and Weill Cornell Medicine. 

The firm touts a new hybridization probe design, which it says will enable small, focused panels that reduce sequencing costs and assay time.

The New York-based firm will use the funding to develop and clinically validate its personalized, real-time tool for monitoring recurrence and treatment response for various sold cancer types. 

The field is collecting evidence supporting genomics-guided care but experts are still awaiting prospective data and grappling with other challenges.

The company, along with Softbank Investment Advisers, is offering a total of 11.5 million shares of its common stock at $84 per share.

Presentations at the American Society of Clinical Oncology's virtual annual meeting included new findings relevant to both blood- and spinal fluid-based approaches.

In the near term, the firm will launch a laboratory-developed, late-stage lung cancer assay out of its lab in Palo Alto. 

The company enters a race to the clinic with several direct competitors, including Guardant Health and CellMax Life, as well as other firms pursuing multi-cancer screening.

Under the agreement, NeoGenomics will also make a $25 million equity investment in Inivata with an option to buy the company outright.

ArcherDx will develop sequencing-based circulating tumor DNA assays for use in AstraZeneca's recently launched Phase III MERMAID-1 trial of durvalumab (Imfinzi).

The Minneapolis-based firm believes the assay can successfully serve as a clinical indicator for patients at risk of developing high-grade prostate cancer (HGPC), thereby improving prostate cancer management. 

The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.

Investigators are building upon an initial case study that allowed them to assess how well ctDNA captured a cancer's full genomic heterogeneity compared to tissue biopsies.

The company was able to increase its total revenue and test revenues despite accessioning fewer samples and fewer billable samples during the quarter.

The company is creating a high-throughput NGS test for healthcare workers and the underserved, and to support viral surveillance programs for large employers.

The firm's precision oncology testing revenue more than doubled to $60.2 million, while its development services revenues contracted 7 percent.

Pages

The Wall Street Journal reports that Russia's announcement of a coronavirus vaccine approval was met with concern as safety testing has not yet been completed.

New Scientist writes there aren't much data available on the accuracy of the two rapid COVID-19 tests the UK plans to roll out.

In PNAS this week: downstream effect of oncoprotein fusion, epigenetic changes influence tRNAs in colon cancer, and more.

Nature News reports that recent proposed changes to the US National Science Foundation have raised concerns about a shift away from the agency's focus on basic research.